Ascelia Pharma AB acquires Oncoral Pharma ApS

June 30, 2017

Ascelia Pharma AB acquires Oncoral Pharma ApS and its novel tablet based proprietary formulation of the chemotherapeutic agent, irinotecan, which today is only available as an intravenous infusion product.

Solural Pharma will continue to support Ascelia Pharma with chemistry manufacturing and control services.

Solural US patent issued

June 20, 2017

The United States Patent and Trademark office has issued the Solural patent “Solid Oral Dosage Form of Testosterone Derivative”.

First human dosing in combination with oral capicitabine tablet

June 1, 2017

Oncoral Pharma ApS initiates first human dosing on Herlev Hospital using a proprietary oral Irinotecan tablet product developed by Solural Pharma in combination therapy with oral capicitabine tablet in adult patients with solid tumors.